Boston Scientific Reports Favorable Results From Precision Spectra SCS System

(RTTNews) - Boston Scientific Corp. (BSX) announced that new retrospective data highlighting the company Precision Spectra Spinal Cord Stimulator or SCS System demonstrate the device provided highly significant pain relief three months after implantation.

The company said Precision Spectra is the first SCS System designed to improve pain relief using the advanced Illumina 3D Software, a three dimensional anatomy-driven computer model. By providing 32 contacts - twice the number of contacts available with other SCS systems - the Precision Spectra System offers more coverage of the spinal cord for the management of chronic pain.

The retrospective study of up to 213 consecutive patients at 13 centers focused on patients with chronic pain who were treated with the Precision Spectra SCS System. Results include: A 94 percent SCS trial therapy success rate (n=213); A highly significant reduction in pain from an average baseline score of 7.8, on a 10-point scale, to an average score of 3.2 at three months post implant (in the patients who have reached the three-month follow up, n=113).